Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C. Leonardi(Harvard University), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Lydia Gedmintas(Bristol-Myers Squibb (Germany)), Suzanne E. Dahlberg(Dana-Farber Cancer Institute), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Mehmet Altan(The University of Texas MD Anderson Cancer Center), Roxana Azimi(Massachusetts Institute of Technology), Justin F. Gainor(Harvard University), Jonathan W. Riess(University of California Davis Medical Center), Matthew D. Hellmann(AstraZeneca (United States)), Sasha Kravets(Dana-Farber Cancer Institute)
Cited by 356
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k